Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia.¶
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., et al. (2001). Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine, 344(14), 1031-1037.
Cited by¶
2 citations across 2 artifacts.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Intervention-Coupled Harm
- The mechanism-switch move replaces the entire mechanism with one whose coupled-harm signature differs — targeted therapy replacing cytotoxic chemotherapy, capability-based security replacing perimeter security — and is the only move that breaks the ratio.
This sourceDemonstrates targeted therapy (imatinib) exploiting a tumour-specific molecular marker rather than division rate, shifting the coupled-harm signature away from marrow toxicity.
- The mechanism-switch move replaces the entire mechanism with one whose coupled-harm signature differs — targeted therapy replacing cytotoxic chemotherapy, capability-based security replacing perimeter security — and is the only move that breaks the ratio.
Domain-specific¶
- Translational Research
- Druker and colleagues' phase I dose-escalation trial tested safety, tolerability, and antileukemic activity, reporting substantial activity and supporting the molecular target's relevance in humans.
This sourcePrimary phase I evidence for translating a molecular target into human treatment. DOI: 10.1056/NEJM200104053441401.
- Druker and colleagues' phase I dose-escalation trial tested safety, tolerability, and antileukemic activity, reporting substantial activity and supporting the molecular target's relevance in humans.
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:21568cec6455 · see in the full table